Features of intensive care for extremely severe course of acute autoimmune demyelinating polyneuroradiculopathy (Guillain-Barré syndrome)
DOI:
https://doi.org/10.22141/2224-0586.16.2.2020.203149Keywords:
acute autoimmune demyelinating polyneuroradiculopathy, Guillain-Barré syndrome, intensive careAbstract
Causes, pathophysiology, modern approaches to the treatment and authors’ experience with the therapy of Guillain-Barré syndrome are considered in this article. Rarity of extremely severe course of disease, vague clinical picture, stereotypeness of treatment could lead to the difficulties for an intensive care physician and complications for a patient. Despite enough number of information about problem, mortality due to acute autoimmune demyelinating polyradiculopathy in developed countries is 5 % in specialized centers that indicates the need for further study of this disease.Downloads
References
Winer J.B. Guillain-Barré syndrome. Mol. Pathol. 2001 Dec. 54 (6). 381-385.
Seneviratne U. Guillain-Barré syndrome. Postgrad. Med. J. 2000 Dec. 76 (902). 774-782. doi: 10.1136/pmj.76.902.774
Jiang G.X., de Pedro-Cuesta J., Strigård K., Olsson T., Link H. Pregnancy and Guillain-Barré syndrome: a nationwide register cohort study. Neuroepidemiology. 1996. 15 (4). 192-200 (ISSN: 0251-5350)
Robert Gormley, Mark S. Riddle, David R. Tribble, and Chad K. Porter. The epidemiology of Guillain-Barré Syndrome in U.S. military personnel: a case-control study. BMC Res. Notes. 2009. 2. 171.
Alshekhlee A., Hussain Z., Sultan B., Katirji B. Guillain-Barré syndrome: incidence and mortality rates in US hospitals. Neurology. 2008. 70 (18). 1608-13 (ISSN: 1526-632X)
Zautner A.E., Johann C., Strubel A., Busse C., Tareen A.M., Masanta W.O., Lugert R., Schmidt-Ott R., Gross U. Seroprevalence of campylobacteriosis and relevant post-infectious sequelae. Eur. J. Clin. Microbiol. Infect. Dis. 2014. 33 (6). 1019-27 (ISSN: 1435-4373)
Dieleman J., Romio S., Johansen K., Weibel D., Bonhoeffer J., Sturkenboom M. Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in Europe. BMJ. 2011. 343. d3908 (ISSN: 1756-1833)
Liang X.F., Li L., Liu D.W., Li K.L., Wu W.D., Zhu B.P., Wang H.Q., Luo H.M., Cao L.S., Zheng J.S., Yin D.P., Cao L., Wu B.B., Bao H.H., Xu D.S., Yang W.Z., Wang Y. Safety of influenza A (H1N1) vaccine in postmarketing surveillance in China. N. Engl. J. Med. 2011. 364 (7). 638-47 (ISSN: 1533-4406)
Khan F., Pallant J.F., Ng L., Bhasker A. Peripheral neuropathy and Guillain-Barré syndrome risks associated with exposure to systemic fluoroquinolones: a pharmacovigilance analysis. Ann. Epidemiol. 2014. 24 (4). 279-85 (ISSN: 1873-2585)
Factors associated with long-term functional outcomes and psychological sequelae in Guillain-Barre syndrome. J. Neurol. 2010. 257 (12). 2024-31 (ISSN: 1432-1459)
Jane Pritchard, Richard A.C. Hughes, Robert D.M. Hadden, Ruth Brassington. Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barré syndrome. Cochrane Systematic Review — Intervention Version published: 15 November 2016.
Richard A.C. Hughes, Ruth Brassington, Angela A. Gunn, Pieter A. van Doorn. Corticosteroids for Guillain-Barré syndrome. Cochrane Systematic Review — Intervention Version published: 24 October 2016.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 O.E. Domoratskyi, V.V. Kryzhevskyi, M.Yu. Svintukovskyi, L.V. Dubinina, H.P. Ivanova

This work is licensed under a Creative Commons Attribution 4.0 International License.